cCARE Fresno
7130 N. Millbrook Ave.
Fresno, CA 93720
Phone: (559)326-1222 Fax: (559)326-1233

Orders

Patient Name: **Botello, Elvira** DOB: **1/8/1952 (73 yrs, 2 mos)** Order Date: **3/25/2025**
Patient Number: **384886** Birth Sex: **Female** Date Printed: **3/17/2025**

BSA: 1.93 (last wt on 3/10/2025) SrCr: 0.82 mg/dL (3/10/2025) CrCl: 89.71 mL/min Wt: 205 lb (93.0 kg), Ht: 62 in (157.5 cm)

Diagnoses:

1/8/2025	Primary	N85.00	Endometrial hyperplasia, unspecified
1/8/2025	Primary	N95.0	Postmenopausal bleeding
1/9/2025	Primary	C54.1	Malignant neoplasm of endometrium
3/10/2025	Primary	E03.9	Hypothyroidism, unspecified
3/10/2025	Primary	E07.9	Disorder of thyroid, unspecified
3/10/2025	Primary	C54.1	Malignant neoplasm of endometrium
3/10/2025	Primary	D50.0	Iron deficiency anemia secondary to blood loss (chronic)

Allergies: No Known Drug Allergies

Regimens: 1) Durvalumab (1120) - CARBOplatin(5-6)D1-PACLitaxel(175)D1 - Q21D f/b Durvalumab (1500) D1 Q28D (1:-1)
2) *Injectafer(Ferric Carboxymaltose)750 mg *contraindicated with dialysis (1:1)

Medications	Regimen dose	Adjustment	Vitals and labs used	Dose to be given	Instructions	Status
Dexamethasone Inj (Decadron, Dexa) IV	10 mg	None	N/A	10 mg	as directed	Planned
Famotidine (Pepcid) IV	20 mg	None	N/A	20 mg	as directed	Planned
Diphenhydramine HCl injection (Benadryl) IV	25 mg	None	N/A	25 mg	as directed	Planned
Durvalumab (Imfinzi) IV	1120 mg	None	N/A	1120 mg	Administer intravenously over 60 minutes through an intravenous line containing a sterile, low-protein binding 0.2 or 0.22 micron in-line filter. Use separate infusion bags and filters for each drug product.	Planned
Paclitaxel inj (Taxol) IV	175 mg/m2	None	1.93 m^2	340 mg	PACLItaxel is an irritant. PACLItaxel should be prepared either in glass or non-PVC containers and administered through non-PVC tubing and a low protein binding in-line filter </=0.22 microns. Final concentration: 0.3-1.2 mg/ml.	Planned
CARBOplatin IV	5 AUC	None	93.0 kg 0.82 mg/dL	573.5 mg	CARBOplatin is an irritant. The FDA has recommended a maximum creatinine clearance for use in calculating CARBOplatin doses to minimize toxicity. The maximum dose is based on a GFR estimate that is capped at 125 mL/min for patients with normal renal function.	Planned
Ferric Carboxymaltose (Injectafer) IV	750 mg	None	N/A	750 mg	Monitor for extravasation. If extravasation occurs, discontinue the Injectafer administration at that site. This iron is contraindicated for pts receiving active dialysis	Planned
Aprepitant (Cinvanti) IV	130 mg	None	N/A	130 mg	Infuse as directed	Planned

Granisetron Extended-Release SQ (Sustol)	10 mg	None	N/A	10 mg	To be given SQ 30 min prior to chemotherapy	Planned

Tests	Specimen	Instructions	Status
CBC,PLT,DIFF	Blood	Quest Test Code- 6399 LabCorp Test Code- 005009	Planned

Workflow	Value	Instructions	Status
Oral Dispensing Plan of Care Assessment	Initial consult	**Counseled by:** ( )Review of d/d interactions ( )Review of potential side effects ( )Review of patient education hand-out / Chemo Education ( )Side effects reported ( )Medication compliant	Planned
CL7	*		Planned
Acuity Level 5	*		Planned
Pharmacy	*		Planned
Treatment-Comment	Select	Physician message ***BMP or CMP to be done within 3-7 days of Carboplatin administration. Any decrease in eGFR of 10 or greater or rise in creatinine of 0.3 or greater needs to be discussed with MD before proceeding with treatment.**	Planned
Treatment Held	Select		Planned
Business Office	Required		Planned
Drug Access and Reimbursement (AstraZeneca)	Pending		Planned
Drug Access and Reimbursement (AstraZeneca)	Pending		Planned
CL2	*		Planned
Acuity Level 2	*		Planned
Pharmacy	*		Planned
Treatment-Comment	Select	Physician message	Planned
Treatment Held	Select		Planned
Business Office	Required		Planned
Drug Access and Reimbursement (Heron Connect)	Pending		Planned
Drug Access			

and Reimbursement (Heron Connect)	Pending		Planned

Ordered By: Sachin Gupta, MD